Navigation Links
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors

Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Cell Signaling Technology, Harvard Medical School and Merrimack Pharmaceuticals collaborated on the MM-121 research. Researchers looked at MM-121 in combination with Erbitux to study efficacy in preclinical cancer models resistant to other targeted therapies.

Cambridge, Mass. (PRWEB) March 16, 2010 -- "Cancer Research" has published the paper “MM-121 Demonstrates in vivo Efficacy in Ligand-Dependent Tumors.” The paper describes how MM-121, an ErbB3 inhibitor, is effective as a single agent in preclinical models of cancer that are driven by known cancer-associated ligands within the cell. The researchers also found that combining MM-121 with an EGFR inhibitor showed efficacy in preclinical cancer models that are resistant to other targeted therapies. The work was completed through a collaboration between Merrimack Pharmaceuticals, Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, the Dana-Farber/Harvard Cancer Center, Cell Signaling Technology and Harvard Medical School. MM-121’s novel mechanism, designed using a systems biology approach, promises to benefit patients not effectively treated by current therapies targeting overexpressed or mutated oncogenes. Merrimack and sanofi-aventis are currently enrolling patients in a Phase 1/2 study of MM-121 combined with the EGFR inhibitor Tarceva® in patients with non small cell lung cancer.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit

Copies of the article can be found at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
2. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
3. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
4. Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
5. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
6. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
7. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
8. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
9. New Report Just Published: World Prostate Cancer Therapeutics Market Report
10. New Report Just Published: World Endoscopy Systems Market Report
11. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Post Your Comments:
Related Image:
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):